Infantile Cerebellar-Retinal Degeneration

Mendelian MONDO:0013802 Pathograph 19 Show in embeddings browser Inborn error of energy metabolism Neurodegenerative disease of infancy

An autosomal recessive neurodegenerative disorder caused by biallelic variants in ACO2, which encodes mitochondrial aconitase - the Krebs-cycle enzyme that isomerises citrate to isocitrate. Children present at two to six months with truncal hypotonia, athetosis and seizures, lose visual tracking that was normal at birth, and go on to bilateral optic atrophy, retinal degeneration and cerebellar atrophy. The mechanistically important finding, and the one that shapes this entry, is a negative result. In the original families the five respiratory-chain complexes and the pyruvate dehydrogenase complex were all normal in muscle mitochondria, while aconitase activity itself was severely reduced in lymphoblasts. So this is not, in that tissue and by that assay, a general oxidative-phosphorylation failure that happens to be caused by a mitochondrial gene. The pathograph is written accordingly: the node downstream of enzyme deficiency is TCA-cycle flux, not OXPHOS. That exclusion is deliberately scoped rather than absolute. It rests on respiratory-chain assays in muscle mitochondria, and the same abstract records that glutamate oxidation there was slightly reduced. Patient fibroblasts, a different tissue, do show deficient cellular respiration and secondary mitochondrial DNA depletion. Both are curated. So the claim this entry makes is that the primary lesion is a Krebs-cycle block and that respiratory-chain failure is not the proximate mechanism, not that oxidative phosphorylation is untouched anywhere. Why the cerebellum and retina specifically, when the enzyme is ubiquitous, is not explained by anything curated here, and the entry records that as a knowledge gap rather than inventing a selective-vulnerability mechanism. Lump/split. ACO2 has a wide allelic spectrum and this entry deliberately covers only part of it. Biallelic variants also cause isolated recessive ophthalmological phenotypes without the neurological syndrome, and - separately and more commonly - monoallelic variants cause dominant isolated optic atrophy, with one European screen finding 50 dominant index cases against 11 biallelic. The dominant disorder is not modelled here as a subtype, because a different mode of inheritance is a split signal rather than a severity gradient: a has_subtypes entry under a recessive disease cannot carry a dominant inheritance. It is recorded in the genetic notes and in a discussion instead, as a separate entity that a future curator should create. No pathophysiology node declares conforms_to. kb/modules/ was searched; the available mitochondrial modules concern respiratory-chain and mtDNA-maintenance failure, which is precisely what this disease was shown not to have.

Ask OpenScientist

Ask a research question about Infantile Cerebellar-Retinal Degeneration. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
4
Pathophys.
13
Phenotypes
2
Gaps
19
Pathograph
1
Genes
2
Medical Actions
1
Models
1
Deep Research
👪

Inheritance

1
Autosomal recessive HP:0000007
The neurological syndrome requires biallelic ACO2 variants. Note that monoallelic ACO2 variants cause a different, dominantly inherited disorder limited to the optic nerve; see the genetic notes.
Autosomal recessive
Show evidence (2 references)
PMID:28463998 SUPPORT Human Clinical
"Infantile cerebellar-retinal degeneration associated with mutations in the mitochondrial aconitase 2 gene (ACO2) has been recently described as a neurodegenerative disease of autosomal recessive inheritance."
States the inheritance pattern and the gene.
PMID:22405087 SUPPORT Human Clinical
"Homozygosity mapping followed by whole-exome sequencing disclosed a Ser112Arg mutation in ACO2, encoding mitochondrial aconitase, a component of the Krebs cycle."
Homozygosity mapping in consanguineous families, consistent with recessive inheritance, and the original gene identification.
?

Discussions and Knowledge Gaps

2
Why does loss of a ubiquitous Krebs-cycle enzyme damage the cerebellum, optic nerve and retina in particular?
KNOWLEDGE GAP OPEN aco2_selective_tissue_vulnerability
Attached to
pathophysiology#Krebs Cycle Flux Block pathophysiology#Progressive Neuronal and Photoreceptor Degeneration
Mitochondrial aconitase is expressed in every tissue with mitochondria, and the enzymatic deficit was demonstrated in lymphoblasts - a cell type that is not clinically affected. Yet the disease is concentrated in cerebellum, optic nerve and retina, with the cortex involved enough to give evolving microcephaly and the muscle apparently spared. Nothing curated here explains this. The usual candidate accounts - high and inflexible energy demand in retinal ganglion cells and their long unmyelinated axons, limited metabolic reserve in cerebellar neurons, or a tissue-specific consequence of substrate accumulation rather than of ATP shortfall - are plausible and untested in this disorder. This gap is not decorative. The same selective vulnerability pattern is what the dominant ACO2 optic atrophy shows in isolation, so whatever explains the tissue selectivity may also explain why a monoallelic dose produces an eye-limited disease while a biallelic dose produces a multisystem one.
Show evidence (1 reference)
PMID:22405087 SUPPORT In Vitro
"Specific aconitase activity in the individuals' lymphoblasts was severely reduced."
Demonstrates the enzymatic deficit in a clinically unaffected cell type, which is what makes the tissue selectivity a real question rather than an artefact of where the enzyme is expressed.
Should dominant ACO2-related isolated optic atrophy be a separate dismech Disease entry?
CURATION TODO OPEN aco2_dominant_optic_atrophy_needs_own_entry
Attached to
genetic#ACO2
Yes, and this entry deliberately leaves room for it rather than absorbing it. Monoallelic ACO2 variants cause isolated dominant optic atrophy, and it is the numerically commoner ACO2 disease: 50 dominant index cases against 11 biallelic in one European screen of unsolved inherited optic neuropathies. It cannot be a has_subtypes record under this entry, because a subtype of a recessive disease cannot carry dominant inheritance, and dismech treats mode of inheritance as a split signal rather than a severity gradient. A third presentation sits between them: biallelic variants causing isolated ophthalmological phenotypes without neurological features. The literature records explicit doubt about whether that entity is real, so it should not be curated as established until that doubt resolves. Recorded as a CURATION_TODO rather than a knowledge gap because the science is settled and the outstanding work is curation.
Show evidence (2 references)
PMID:34056600 SUPPORT Human Clinical
"Here, we report the identification of 50 index cases carrying heterozygous pathogenic ACO2 variants, together with 11 index cases with biallelic ACO2 mutations."
Establishes that the dominant entity exists and is numerically substantial, which is the case for giving it its own entry.
PMID:32449285 SUPPORT INDIRECT Human Clinical
"However, some doubt remains as to whether biallelic ACO2 variants can cause isolated ophthalmologic phenotypes."
Supports leaving the third, recessive eye-limited presentation uncurated for now. Marked INDIRECT because it reports uncertainty rather than a finding.
⚙

Pathophysiology

4
Biallelic ACO2 Loss-of-Function Variants
Homozygous or compound heterozygous variants in ACO2. The founding families carried a homozygous Ser112Arg substitution identified by homozygosity mapping with exome sequencing.
Genetic context variant_origin: GERMLINE functional_impact_category: LOSS_OF_FUNCTION
Downstream
Reduced Mitochondrial Aconitase Activity The variant enzyme retains little catalytic activity.
Show evidence (3 references)
PMID:22405087 SUPPORT INDIRECT In Vitro
"Under restrictive conditions, the mutant human ACO2 failed to complement a yeast ACO1 deletion strain, whereas the wild-type human ACO2 succeeded, indicating that this mutation is pathogenic."
This is the sentence that demonstrates loss of function, as opposed to the mapping sentence above which identifies the variant. Marked INDIRECT because the demonstration is heterologous complementation in yeast rather than a measurement in human tissue.
PMID:22405087 SUPPORT Human Clinical
"Homozygosity mapping followed by whole-exome sequencing disclosed a Ser112Arg mutation in ACO2, encoding mitochondrial aconitase, a component of the Krebs cycle."
The original identification of the causative variant and gene.
PMID:30689204 SUPPORT Human Clinical
"Subsequently, additional studies reported patients with pathogenic ACO2 variants, further expanding the genetic and clinical spectrum of this disorder to include milder and later onset manifestations."
Establishes allelic and phenotypic heterogeneity beyond the founding families.
Reduced Mitochondrial Aconitase Activity
Loss of the enzyme that converts citrate to isocitrate via cis-aconitate. This was measured directly in patient lymphoblasts and found severely reduced, which is what makes the enzymatic deficit an observation rather than an inference from the genotype.
mitochondrial aconitase activity GO:0003994 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased mitochondrial aconitase activity, annotated with aconitate hydratase activity (GO:0003994). GO:0003994 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Krebs Cycle Flux Block The citrate-to-isocitrate step is the committed point the enzyme catalyses, so its loss interrupts flux through the cycle.
Show evidence (1 reference)
PMID:22405087 SUPPORT In Vitro
"Specific aconitase activity in the individuals' lymphoblasts was severely reduced."
Direct measurement of the enzymatic deficit in patient cells.
Krebs Cycle Flux Block
An isolated interruption of the tricarboxylic acid cycle. This node, rather than a respiratory-chain node, is where the mechanism sits, because the respiratory chain was measured and found intact. Plasma metabolomics in affected patients yields a diagnostic metabolic fingerprint, which is consistent with an accumulating upstream substrate pool rather than with a general failure of mitochondrial energy production.
tricarboxylic acid cycle GO:0006099 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased tricarboxylic acid cycle (GO:0006099). GO:0006099 is a biological process from the Gene Ontology. ↓ DECREASED
Experimental models
Patient-derived skin fibroblasts with compound heterozygous ACO2 variants PRIMARY CELL CULTURE Reports the cellular consequences of the aconitase block in patient tissue: deficient respiration, mitochondrial DNA depletion, and altered expression of TCA and electron-transport components.
Downstream
Progressive Neuronal and Photoreceptor Degeneration The proposed route from the metabolic block to tissue loss. The selective vulnerability of cerebellum, optic nerve and retina is not explained by anything curated here; see the knowledge gap.
Show evidence (3 references)
PMID:26992325 SUPPORT In Vitro
"We also observed a deficiency in cellular respiration and, for the first time, demonstrate evidence of mitochondrial DNA depletion and altered expression of some TCA components and electron transport chain subunits."
Records the downstream consequences seen in patient fibroblasts. Curated to keep the entry's OXPHOS exclusion honest: the respiratory-chain normality is a muscle-mitochondria result, and in fibroblasts respiration is impaired and mtDNA is depleted. This does not displace the flux block as the primary lesion; it bounds the claim to the tissue in which it was measured.
PMID:22405087 REFUTE Human Clinical
"The activities of the five enzymatic complexes of the mitochondrial respiratory chain and the pyruvate dehydrogenase complex were normal in isolated mitochondria from muscle."
Recorded as REFUTE against the alternative that this disease acts through respiratory-chain failure. It is the measurement that localises the lesion to the Krebs cycle itself, and it is the reason this node is not an oxidative-phosphorylation node.
PMID:28463998 SUPPORT Human Clinical
"Taken together we report a diagnostic metabolic fingerprint for mitochondrial aconitase 2 deficiency."
A measurable plasma metabolite signature, which supports a defined metabolic block at this node.
Progressive Neuronal and Photoreceptor Degeneration
Degeneration concentrated in the cerebellum, the optic nerve and the retina, with evolving microcephaly indicating that the cerebral cortex is also affected. Vision is normal in the newborn period and then deteriorates, so the process is degenerative rather than a failure of development.
retinal ganglion cell CL:0000740 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal ganglion cell (CL:0000740). CL:0000740 is a cell type from the Cell Ontology.
cerebellum UBERON:0002037 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebellum (UBERON:0002037). UBERON:0002037 is an anatomical location from the Uberon multi-species anatomy ontology. retina UBERON:0000966 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in retina (UBERON:0000966). UBERON:0000966 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Axial hypotonia
Truncal ataxia
Athetosis
Seizure
Optic atrophy
Retinal dystrophy
Cerebellar atrophy
Progressive microcephaly
Esotropia
Global developmental delay
Intellectual disability
Absent speech
Cerebral atrophy The atrophy is global rather than confined to the cerebellum, and the supratentorial component is what the cortical-atrophy reports describe.
Show evidence (2 references)
PMID:22405087 SUPPORT Human Clinical
"Visual tracking, normal at the newborn period, steadily deteriorated with the gradual evolution of bilateral optic atrophy."
Establishes the degenerative rather than developmental character of the visual loss, which is what this node claims.
PMID:30689204 SUPPORT Human Clinical
"Most patients present in early infancy with severe truncal hypotonia, truncal ataxia, variable seizures, evolving microcephaly, and ophthalmological abnormalities of which the most dominant are esotropia and optic atrophy with later development of retinal dystrophy."
The consolidated phenotype across 16 patients, and the source for the individual phenotype records below.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Infantile Cerebellar-Retinal Degeneration Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Eye 3
Optic atrophy HP:0000648 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bilateral optic atrophy, annotated with Optic atrophy (HP:0000648). HP:0000648 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22405087 SUPPORT Human Clinical
"Visual tracking, normal at the newborn period, steadily deteriorated with the gradual evolution of bilateral optic atrophy."
Documents the optic atrophy and its evolution from a normal baseline.
Retinal dystrophy HP:0000556 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Retinal degeneration, annotated with Retinal dystrophy (HP:0000556). HP:0000556 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30689204 SUPPORT Human Clinical
"optic atrophy with later development of retinal dystrophy"
Documents the retinal dystrophy and that it follows the optic atrophy.
Esotropia HP:0000565 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Esotropia (HP:0000565). HP:0000565 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30689204 SUPPORT Human Clinical
"ophthalmological abnormalities of which the most dominant are esotropia and optic atrophy"
Documents esotropia as a dominant ophthalmological feature.
Head and Neck 1
Progressive microcephaly HP:0000253 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Evolving microcephaly, annotated with Progressive microcephaly (HP:0000253). HP:0000253 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30689204 SUPPORT Human Clinical
"Most patients present in early infancy with severe truncal hypotonia, truncal ataxia, variable seizures, evolving microcephaly, and ophthalmological abnormalities of which the most dominant are esotropia and optic atrophy with later development of retinal dystrophy."
Documents that the microcephaly is acquired, which is what distinguishes HP:0000253 from congenital microcephaly.
Musculoskeletal 1
Axial hypotonia HP:0008936 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Truncal hypotonia, annotated with Axial hypotonia (HP:0008936). HP:0008936 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:22405087 SUPPORT Human Clinical
"We studied eight individuals from two unrelated families who presented at 2-6 months of age with truncal hypotonia and athetosis, seizure disorder, and ophthalmologic abnormalities."
Documents truncal hypotonia at presentation with the age range.
PMID:30689204 SUPPORT Human Clinical
"Most patients present in early infancy with severe truncal hypotonia"
Confirms truncal hypotonia as a presenting feature across a larger series.
Nervous System 8
Truncal ataxia HP:0002078 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Truncal ataxia (HP:0002078). HP:0002078 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30689204 SUPPORT Human Clinical
"severe truncal hypotonia, truncal ataxia, variable seizures"
Documents truncal ataxia in the consolidated series.
Athetosis HP:0002305 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Athetosis (HP:0002305). HP:0002305 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22405087 SUPPORT Human Clinical
"presented at 2-6 months of age with truncal hypotonia and athetosis"
Documents athetosis at presentation.
Seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizures, annotated with Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:22405087 SUPPORT Human Clinical
"truncal hypotonia and athetosis, seizure disorder, and ophthalmologic abnormalities"
Documents the seizure disorder at presentation.
PMID:30689204 SUPPORT Human Clinical
"Most patients present in early infancy with severe truncal hypotonia, truncal ataxia, variable seizures, evolving microcephaly, and ophthalmological abnormalities of which the most dominant are esotropia and optic atrophy with later development of retinal dystrophy."
Records that seizures are variable rather than universal across the series.
Cerebellar atrophy HP:0001272 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar atrophy (HP:0001272). HP:0001272 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:22405087 SUPPORT Human Clinical
"Serial brain MRI displayed progressive, prominent cerebellar atrophy accompanied by thinning of the corpus callosum, dysmyelination, and frontal and temporal cortical atrophy."
Serial imaging documenting progressive cerebellar atrophy, and in the same sentence the cortical atrophy that accompanies the evolving microcephaly.
PMID:22405087 SUPPORT Human Clinical
"Thereafter, repeated MR scans (Figure 2) displayed progressive cerebellar atrophy of both hemispheres and the vermis."
Localises the atrophy to both cerebellar hemispheres and the vermis, and establishes that it is progressive on repeat imaging.
Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22405087 SUPPORT Human Clinical
"Their course was characterized by failure to acquire developmental milestones and culminated in profound psychomotor retardation and progressive visual loss, including optic nerve and retinal atrophy."
States the developmental failure directly, in the founding cohort.
Intellectual disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Profound psychomotor retardation, annotated with Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22405087 SUPPORT Human Clinical
"Their course was characterized by failure to acquire developmental milestones and culminated in profound psychomotor retardation and progressive visual loss, including optic nerve and retinal atrophy."
The same sentence reports the cognitive endpoint. Curated as a separate phenotype from the developmental delay because the schema treats the delay and its outcome as different records.
Absent speech HP:0001344 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Failure to acquire language, annotated with Absent speech (HP:0001344). HP:0001344 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30689204 SUPPORT Human Clinical
"Most patients remain nonambulatory and do no acquire any language, but a subgroup of patients share a more favorable course."
Source for both the language failure and the explicit exception, in the largest assembled cohort. The sentence carries its own qualification, which is why no frequency band is asserted.
Cerebral atrophy HP:0002059 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Frontal and temporal cortical atrophy, annotated with Cerebral atrophy (HP:0002059). HP:0002059 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22405087 SUPPORT Human Clinical
"Serial brain MRI displayed progressive, prominent cerebellar atrophy accompanied by thinning of the corpus callosum, dysmyelination, and frontal and temporal cortical atrophy."
Names the supratentorial findings alongside the cerebellar ones. The same sentence is already quoted under the cerebellar-atrophy record, where the cortical component it reports was not modelled as its own phenotype.
🧬

Genetic Associations

1
ACO2
Gene: ACO2 hgnc:118 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ACO2 (hgnc:118). hgnc:118 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (3 references)
PMID:34056600 SUPPORT Human Clinical
"By screening European cohorts of individuals with genetically unsolved inherited optic neuropathies, we identified 61 cases harbouring variants in ACO2, among whom 50 carried dominant mutations, emphasizing for the first time the important contribution of ACO2 monoallelic pathogenic variants to..."
Establishes the dominant optic atrophy entity and its numerical weight relative to biallelic disease.
PMID:34056600 SUPPORT Human Clinical
"Here, we report the identification of 50 index cases carrying heterozygous pathogenic ACO2 variants, together with 11 index cases with biallelic ACO2 mutations."
Quantifies the dominant and recessive case counts recorded in the notes.
PMID:32449285 SUPPORT INDIRECT Human Clinical
"However, some doubt remains as to whether biallelic ACO2 variants can cause isolated ophthalmologic phenotypes."
Records the stated uncertainty about the recessive eye-limited phenotype. Marked INDIRECT because it reports the state of the argument rather than establishing or excluding the phenotype.
💊

Medical Actions

2
Triheptanoin anaplerotic therapy
Action: anaplerotic therapy with triheptanoinNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is anaplerotic therapy with triheptanoin, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Platform: Small molecule
Triheptanoin, a C7 triglyceride, given to two brothers with ACO2 deficiency. It is anaplerotic: its odd-chain metabolites enter the Krebs cycle as succinyl-CoA, downstream of the aconitase step, so it refills cycle intermediates without requiring the blocked enzyme. Motor abilities improved in both patients. This is the only treatment curated here that acts on the mechanism rather than on its consequences.
Mechanism Target:
Krebs Cycle Flux Block — Bypasses the aconitase step by supplying anaplerotic substrate that enters the cycle below the block, which is why it can help without restoring aconitase activity.
Show evidence (1 reference)
PMID:38668366 SUPPORT Human Clinical
"In an in vivo trial, triheptanoin was used to bypass the defective aconitase 2 and fill up the citric acid cycle. Motor abilities in both patients improved."
States both the mechanistic rationale and the outcome. The n of two and the absence of a control are recorded in notes rather than in the grade.
Supportive and rehabilitative care
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Platform: Behavioral / lifestyle
Management is otherwise symptomatic: seizure control, feeding and respiratory support, and physical therapy for the hypotonia and ataxia. Nothing in this tier addresses the enzymatic defect.
🔬

Diagnosis

2
Plasma metabolomic fingerprint
Untargeted plasma metabolomics yields a metabolite signature reported as diagnostic for mitochondrial aconitase deficiency. This is a useful adjunct precisely because the standard mitochondrial workup is unhelpful here: the respiratory-chain complexes are normal, so a muscle biopsy assay of the complexes will not point at this gene.
Show evidence (2 references)
PMID:28463998 SUPPORT Human Clinical
"Taken together we report a diagnostic metabolic fingerprint for mitochondrial aconitase 2 deficiency."
States the diagnostic claim this record describes.
PMID:22405087 SUPPORT INDIRECT Human Clinical
"The activities of the five enzymatic complexes of the mitochondrial respiratory chain and the pyruvate dehydrogenase complex were normal in isolated mitochondria from muscle."
Supports the rationale in this record's description, that a conventional respiratory-chain workup will be normal. Marked INDIRECT because it reports a negative enzymology result rather than evaluating a diagnostic test.
ACO2 sequencing
Molecular confirmation. Because the biochemical workup that would normally localise a mitochondrial disease is normal in this disorder, sequencing is effectively the primary diagnostic route rather than a confirmatory one.
Show evidence (1 reference)
PMID:22405087 SUPPORT Human Clinical
"Homozygosity mapping followed by whole-exome sequencing disclosed a Ser112Arg mutation in ACO2"
The genomic route by which the disease was originally identified.
📊

Prevalence

1
Worldwide, reported cases
Cases In Literature Ultra Rare
Recorded as a case count rather than a rate because no denominator exists. The largest assembled series is 16 patients; the founding report described eight individuals from two families. A 2024 report puts the cumulative total at roughly 100 patients with aconitase 2 deficiency, which spans the whole ACO2 allelic series including the milder OPA9 end rather than this entry alone.
Show evidence (1 reference)
PMID:30689204 SUPPORT Human Clinical
"Here, we report an international multicenter cohort of 16 patients (of whom 7 are newly diagnosed) with biallelic pathogenic variants in ACO2 gene."
The largest single assembled cohort, which is the basis for the ULTRA_RARE band.
🧫

Experimental Models

1
Patient-derived skin fibroblasts with compound heterozygous ACO2 variants PRIMARY_CELL_CULTURE
Fibroblasts from a patient with compound heterozygous ACO2 missense variants of uncertain significance, used to establish pathogenicity functionally and to characterise the downstream metabolic consequences.
Publication
PMID:26992325
Pathograph links
Krebs Cycle Flux Block measures fidelity: moderate observes: cellular Reports the cellular consequences of the aconitase block in patient tissue: deficient respiration, mitochondrial DNA depletion, and altered expression of TCA and electron-transport components.
Limitations: Fibroblasts are not an affected tissue in this disorder, which targets cerebellum and retina, so the findings establish that the variants are pathogenic and that consequences propagate beyond aconitase itself, not that these are the events that kill neurons and photoreceptors. A single patient's cells.
Show evidence (1 reference)
PMID:26992325 SUPPORT In Vitro
"Our findings demonstrate the pathogenicity of two VUS in ACO2, provide novel mechanistic insights to TCA disturbances in ACO2 deficiency, and implicate mitochondrial DNA depletion in the pathogenesis of this recently described disorder."
The authors' own statement of what the model establishes, which is pathogenicity plus a downstream mechanism rather than a disease model.
Notes
No animal model is curated. The review that prompted this section proposed a skeletal-muscle-specific Aco2 knockout mouse (PMID:41331265) and an A252T knock-in mouse (PMID:38007539). Both were fetched and read: the first is titled "Critical role of mitochondrial aconitase in skeletal muscle maturation" and studies unloading-induced muscle atrophy; the second is titled "ACO2 deficiency increases vulnerability to Parkinson's disease" and studies dopaminergic neurodegeneration. Neither mentions infantile cerebellar-retinal degeneration at all. They share the gene, not the disease, and curating either as a model of this disorder would be the gene-mediated Named Entity Confusion the curation rules warn about.
{ }

Source YAML

click to show 
name: Infantile Cerebellar-Retinal Degeneration
creation_date: "2026-09-12T13:50:00Z"
category: Mendelian
synonyms:
- ICRD
- infantile cerebellar retinal degeneration
- ACO2 deficiency
- mitochondrial aconitase deficiency
- cerebellar-retinal degeneration, infantile
description: >-
  An autosomal recessive neurodegenerative disorder caused by biallelic variants
  in ACO2, which encodes mitochondrial aconitase - the Krebs-cycle enzyme that
  isomerises citrate to isocitrate. Children present at two to six months with
  truncal hypotonia, athetosis and seizures, lose visual tracking that was normal
  at birth, and go on to bilateral optic atrophy, retinal degeneration and
  cerebellar atrophy.

  The mechanistically important finding, and the one that shapes this entry, is a
  negative result. In the original families the five respiratory-chain complexes
  and the pyruvate dehydrogenase complex were all normal in muscle mitochondria,
  while aconitase activity itself was severely reduced in lymphoblasts. So this
  is not, in that tissue and by that assay, a general oxidative-phosphorylation
  failure that happens to be caused by a mitochondrial gene. The pathograph is
  written accordingly: the node downstream of enzyme deficiency is TCA-cycle
  flux, not OXPHOS.

  That exclusion is deliberately scoped rather than absolute. It rests on
  respiratory-chain assays in muscle mitochondria, and the same abstract records
  that glutamate oxidation there was slightly reduced. Patient fibroblasts, a
  different tissue, do show deficient cellular respiration and secondary
  mitochondrial DNA depletion. Both are curated. So the claim this entry makes is
  that the primary lesion is a Krebs-cycle block and that respiratory-chain
  failure is not the proximate mechanism, not that oxidative phosphorylation is
  untouched anywhere.

  Why the cerebellum and retina specifically, when the enzyme is ubiquitous, is
  not explained by anything curated here, and the entry records that as a
  knowledge gap rather than inventing a selective-vulnerability mechanism.

  Lump/split. ACO2 has a wide allelic spectrum and this entry deliberately covers
  only part of it. Biallelic variants also cause isolated recessive
  ophthalmological phenotypes without the neurological syndrome, and - separately
  and more commonly - monoallelic variants cause dominant isolated optic atrophy,
  with one European screen finding 50 dominant index cases against 11 biallelic.
  The dominant disorder is not modelled here as a subtype, because a different
  mode of inheritance is a split signal rather than a severity gradient: a
  has_subtypes entry under a recessive disease cannot carry a dominant
  inheritance. It is recorded in the genetic notes and in a discussion instead,
  as a separate entity that a future curator should create.

  No pathophysiology node declares conforms_to. kb/modules/ was searched; the
  available mitochondrial modules concern respiratory-chain and mtDNA-maintenance
  failure, which is precisely what this disease was shown not to have.
disease_term:
  preferred_term: infantile cerebellar-retinal degeneration
  term:
    id: MONDO:0013802
    label: infantile cerebellar-retinal degeneration
parents:
- Inborn error of energy metabolism
- Neurodegenerative disease of infancy
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    The neurological syndrome requires biallelic ACO2 variants. Note that
    monoallelic ACO2 variants cause a different, dominantly inherited disorder
    limited to the optic nerve; see the genetic notes.
  evidence:
  - reference: PMID:28463998
    reference_title: "Plasma metabolomics reveals a diagnostic metabolic fingerprint for mitochondrial aconitase (ACO2) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infantile cerebellar-retinal degeneration associated with mutations in the mitochondrial aconitase 2 gene (ACO2) has been recently described as a neurodegenerative disease of autosomal recessive inheritance."
    explanation: >-
      States the inheritance pattern and the gene.
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Homozygosity mapping followed by whole-exome sequencing disclosed a Ser112Arg mutation in ACO2, encoding mitochondrial aconitase, a component of the Krebs cycle."
    explanation: >-
      Homozygosity mapping in consanguineous families, consistent with recessive
      inheritance, and the original gene identification.
pathophysiology:
- name: Biallelic ACO2 Loss-of-Function Variants
  biological_scale: MOLECULAR
  description: >-
    Homozygous or compound heterozygous variants in ACO2. The founding families
    carried a homozygous Ser112Arg substitution identified by homozygosity mapping
    with exome sequencing.
  genetic_context:
    variant_origin: GERMLINE
    functional_impact_category: LOSS_OF_FUNCTION
  downstream:
  - target: Reduced Mitochondrial Aconitase Activity
    description: >-
      The variant enzyme retains little catalytic activity.
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: "Under restrictive conditions, the mutant human ACO2 failed to complement a yeast ACO1 deletion strain, whereas the wild-type human ACO2 succeeded, indicating that this mutation is pathogenic."
    explanation: >-
      This is the sentence that demonstrates loss of function, as opposed to the
      mapping sentence above which identifies the variant. Marked INDIRECT because
      the demonstration is heterologous complementation in yeast rather than a
      measurement in human tissue.
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Homozygosity mapping followed by whole-exome sequencing disclosed a Ser112Arg mutation in ACO2, encoding mitochondrial aconitase, a component of the Krebs cycle."
    explanation: >-
      The original identification of the causative variant and gene.
  - reference: PMID:30689204
    reference_title: "Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subsequently, additional studies reported patients with pathogenic ACO2 variants, further expanding the genetic and clinical spectrum of this disorder to include milder and later onset manifestations."
    explanation: >-
      Establishes allelic and phenotypic heterogeneity beyond the founding
      families.
- name: Reduced Mitochondrial Aconitase Activity
  biological_scale: MOLECULAR
  description: >-
    Loss of the enzyme that converts citrate to isocitrate via cis-aconitate. This
    was measured directly in patient lymphoblasts and found severely reduced,
    which is what makes the enzymatic deficit an observation rather than an
    inference from the genotype.
  molecular_functions:
  - preferred_term: mitochondrial aconitase activity
    modifier: DECREASED
    term:
      id: GO:0003994
      label: aconitate hydratase activity
  downstream:
  - target: Krebs Cycle Flux Block
    description: >-
      The citrate-to-isocitrate step is the committed point the enzyme catalyses,
      so its loss interrupts flux through the cycle.
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Specific aconitase activity in the individuals' lymphoblasts was severely reduced."
    explanation: >-
      Direct measurement of the enzymatic deficit in patient cells.
- name: Krebs Cycle Flux Block
  biological_scale: MOLECULAR
  description: >-
    An isolated interruption of the tricarboxylic acid cycle. This node, rather
    than a respiratory-chain node, is where the mechanism sits, because the
    respiratory chain was measured and found intact. Plasma metabolomics in
    affected patients yields a diagnostic metabolic fingerprint, which is
    consistent with an accumulating upstream substrate pool rather than with a
    general failure of mitochondrial energy production.
  biological_processes:
  - preferred_term: tricarboxylic acid cycle
    modifier: DECREASED
    term:
      id: GO:0006099
      label: tricarboxylic acid cycle
  downstream:
  - target: Progressive Neuronal and Photoreceptor Degeneration
    description: >-
      The proposed route from the metabolic block to tissue loss. The selective
      vulnerability of cerebellum, optic nerve and retina is not explained by
      anything curated here; see the knowledge gap.
  evidence:
  - reference: PMID:26992325
    reference_title: "Functional cellular analyses reveal energy metabolism defect and mitochondrial DNA depletion in a case of mitochondrial aconitase deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We also observed a deficiency in cellular respiration and, for the first time, demonstrate evidence of mitochondrial DNA depletion and altered expression of some TCA components and electron transport chain subunits."
    explanation: >-
      Records the downstream consequences seen in patient fibroblasts. Curated to
      keep the entry's OXPHOS exclusion honest: the respiratory-chain normality is
      a muscle-mitochondria result, and in fibroblasts respiration is impaired and
      mtDNA is depleted. This does not displace the flux block as the primary
      lesion; it bounds the claim to the tissue in which it was measured.
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "The activities of the five enzymatic complexes of the mitochondrial respiratory chain and the pyruvate dehydrogenase complex were normal in isolated mitochondria from muscle."
    explanation: >-
      Recorded as REFUTE against the alternative that this disease acts through
      respiratory-chain failure. It is the measurement that localises the lesion
      to the Krebs cycle itself, and it is the reason this node is not an
      oxidative-phosphorylation node.
  - reference: PMID:28463998
    reference_title: "Plasma metabolomics reveals a diagnostic metabolic fingerprint for mitochondrial aconitase (ACO2) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Taken together we report a diagnostic metabolic fingerprint for mitochondrial aconitase 2 deficiency."
    explanation: >-
      A measurable plasma metabolite signature, which supports a defined
      metabolic block at this node.
- name: Progressive Neuronal and Photoreceptor Degeneration
  biological_scale: TISSUE
  description: >-
    Degeneration concentrated in the cerebellum, the optic nerve and the retina,
    with evolving microcephaly indicating that the cerebral cortex is also
    affected. Vision is normal in the newborn period and then deteriorates, so the
    process is degenerative rather than a failure of development.
  locations:
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  cell_types:
  - preferred_term: retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  downstream:
  - target: Axial hypotonia
  - target: Truncal ataxia
  - target: Athetosis
  - target: Seizure
  - target: Optic atrophy
  - target: Retinal dystrophy
  - target: Cerebellar atrophy
  - target: Progressive microcephaly
  - target: Esotropia
  - target: Global developmental delay
  - target: Intellectual disability
  - target: Absent speech
  - target: Cerebral atrophy
    description: >-
      The atrophy is global rather than confined to the cerebellum, and the
      supratentorial component is what the cortical-atrophy reports describe.
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Visual tracking, normal at the newborn period, steadily deteriorated with the gradual evolution of bilateral optic atrophy."
    explanation: >-
      Establishes the degenerative rather than developmental character of the
      visual loss, which is what this node claims.
  - reference: PMID:30689204
    reference_title: "Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients present in early infancy with severe truncal hypotonia, truncal ataxia, variable seizures, evolving microcephaly, and ophthalmological abnormalities of which the most dominant are esotropia and optic atrophy with later development of retinal dystrophy."
    explanation: >-
      The consolidated phenotype across 16 patients, and the source for the
      individual phenotype records below.
phenotypes:
- category: Neurologic
  name: Axial hypotonia
  description: >-
    Severe truncal hypotonia, the usual presenting sign, appearing at two to six
    months of age.
  phenotype_term:
    preferred_term: Truncal hypotonia
    term:
      id: HP:0008936
      label: Axial hypotonia
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We studied eight individuals from two unrelated families who presented at 2-6 months of age with truncal hypotonia and athetosis, seizure disorder, and ophthalmologic abnormalities."
    explanation: >-
      Documents truncal hypotonia at presentation with the age range.
  - reference: PMID:30689204
    reference_title: "Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients present in early infancy with severe truncal hypotonia"
    explanation: >-
      Confirms truncal hypotonia as a presenting feature across a larger series.
- category: Neurologic
  name: Truncal ataxia
  description: >-
    Ataxia of the trunk, consistent with the cerebellar component of the
    degeneration.
  phenotype_term:
    preferred_term: Truncal ataxia
    term:
      id: HP:0002078
      label: Truncal ataxia
  evidence:
  - reference: PMID:30689204
    reference_title: "Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe truncal hypotonia, truncal ataxia, variable seizures"
    explanation: >-
      Documents truncal ataxia in the consolidated series.
- category: Neurologic
  name: Athetosis
  description: >-
    Slow writhing involuntary movements, present from the initial presentation in
    the founding families.
  phenotype_term:
    preferred_term: Athetosis
    term:
      id: HP:0002305
      label: Athetosis
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presented at 2-6 months of age with truncal hypotonia and athetosis"
    explanation: >-
      Documents athetosis at presentation.
- category: Neurologic
  name: Seizure
  description: >-
    A seizure disorder, present in the founding families and variable across the
    wider series.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "truncal hypotonia and athetosis, seizure disorder, and ophthalmologic abnormalities"
    explanation: >-
      Documents the seizure disorder at presentation.
  - reference: PMID:30689204
    reference_title: "Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients present in early infancy with severe truncal hypotonia, truncal ataxia, variable seizures, evolving microcephaly, and ophthalmological abnormalities of which the most dominant are esotropia and optic atrophy with later development of retinal dystrophy."
    explanation: >-
      Records that seizures are variable rather than universal across the series.
- category: Ophthalmologic
  name: Optic atrophy
  description: >-
    Bilateral optic atrophy evolving after a period of normal visual tracking,
    described as one of the two dominant ophthalmological features.
  phenotype_term:
    preferred_term: Bilateral optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Visual tracking, normal at the newborn period, steadily deteriorated with the gradual evolution of bilateral optic atrophy."
    explanation: >-
      Documents the optic atrophy and its evolution from a normal baseline.
- category: Ophthalmologic
  name: Retinal dystrophy
  description: >-
    Retinal degeneration developing later than the optic atrophy, which is the
    sequence recorded in the consolidated series.
  phenotype_term:
    preferred_term: Retinal degeneration
    term:
      id: HP:0000556
      label: Retinal dystrophy
  evidence:
  - reference: PMID:30689204
    reference_title: "Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "optic atrophy with later development of retinal dystrophy"
    explanation: >-
      Documents the retinal dystrophy and that it follows the optic atrophy.
- category: Ophthalmologic
  name: Esotropia
  description: >-
    Convergent strabismus, described alongside optic atrophy as the most dominant
    ophthalmological abnormality.
  phenotype_term:
    preferred_term: Esotropia
    term:
      id: HP:0000565
      label: Esotropia
  evidence:
  - reference: PMID:30689204
    reference_title: "Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmological abnormalities of which the most dominant are esotropia and optic atrophy"
    explanation: >-
      Documents esotropia as a dominant ophthalmological feature.
- category: Neurologic
  name: Cerebellar atrophy
  description: >-
    Cerebellar atrophy on neuroimaging, the structural correlate of the truncal
    ataxia and the feature that gives the disorder its name.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  reports_on:
  - target: Progressive Neuronal and Photoreceptor Degeneration
    relationship: READOUT_OF
    description: >-
      Neuroimaging atrophy is a structural readout of the degeneration node.
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serial brain MRI displayed progressive, prominent cerebellar atrophy accompanied by thinning of the corpus callosum, dysmyelination, and frontal and temporal cortical atrophy."
    explanation: >-
      Serial imaging documenting progressive cerebellar atrophy, and in the same
      sentence the cortical atrophy that accompanies the evolving microcephaly.
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thereafter, repeated MR scans (Figure 2) displayed progressive cerebellar atrophy of both hemispheres and the vermis."
    explanation: >-
      Localises the atrophy to both cerebellar hemispheres and the vermis, and
      establishes that it is progressive on repeat imaging.
- category: Neurologic
  name: Progressive microcephaly
  description: >-
    Microcephaly that evolves after birth rather than being present at birth,
    consistent with a degenerative rather than a developmental process.
  phenotype_term:
    preferred_term: Evolving microcephaly
    term:
      id: HP:0000253
      label: Progressive microcephaly
  evidence:
  - reference: PMID:30689204
    reference_title: "Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients present in early infancy with severe truncal hypotonia, truncal ataxia, variable seizures, evolving microcephaly, and ophthalmological abnormalities of which the most dominant are esotropia and optic atrophy with later development of retinal dystrophy."
    explanation: >-
      Documents that the microcephaly is acquired, which is what distinguishes
      HP:0000253 from congenital microcephaly.
- category: Neurologic
  name: Global developmental delay
  description: >-
    Failure to acquire developmental milestones from infancy, the dominant
    functional consequence of the disorder.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Their course was characterized by failure to acquire developmental milestones and culminated in profound psychomotor retardation and progressive visual loss, including optic nerve and retinal atrophy."
    explanation: >-
      States the developmental failure directly, in the founding cohort.
- category: Neurologic
  name: Intellectual disability
  description: >-
    Profound psychomotor retardation is the reported outcome in most patients,
    though the phenotype is a genuine spectrum and a subgroup does better.
  phenotype_term:
    preferred_term: Profound psychomotor retardation
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Their course was characterized by failure to acquire developmental milestones and culminated in profound psychomotor retardation and progressive visual loss, including optic nerve and retinal atrophy."
    explanation: >-
      The same sentence reports the cognitive endpoint. Curated as a separate
      phenotype from the developmental delay because the schema treats the delay
      and its outcome as different records.
- category: Neurologic
  name: Absent speech
  description: >-
    Most patients acquire no language. Recorded with the qualification the source
    itself makes: a subgroup follows a more favourable course.
  phenotype_term:
    preferred_term: Failure to acquire language
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:30689204
    reference_title: "Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients remain nonambulatory and do no acquire any language, but a subgroup of patients share a more favorable course."
    explanation: >-
      Source for both the language failure and the explicit exception, in the
      largest assembled cohort. The sentence carries its own qualification, which
      is why no frequency band is asserted.
- category: Neurologic
  name: Cerebral atrophy
  description: >-
    Supratentorial atrophy accompanying the predominant cerebellar involvement,
    with thinning of the corpus callosum and dysmyelination.
  phenotype_term:
    preferred_term: Frontal and temporal cortical atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serial brain MRI displayed progressive, prominent cerebellar atrophy accompanied by thinning of the corpus callosum, dysmyelination, and frontal and temporal cortical atrophy."
    explanation: >-
      Names the supratentorial findings alongside the cerebellar ones. The same
      sentence is already quoted under the cerebellar-atrophy record, where the
      cortical component it reports was not modelled as its own phenotype.
genetic:
- name: ACO2
  gene_term:
    preferred_term: ACO2
    term:
      id: hgnc:118
      label: ACO2
  relationship_type: CAUSATIVE
  notes: >-
    ACO2 encodes mitochondrial aconitase, a Krebs-cycle enzyme. Its allelic
    spectrum spans three clinically distinct presentations, and only the first is
    curated in this entry.

    Biallelic variants cause this infantile neurological syndrome. Biallelic
    variants can also cause isolated ophthalmological phenotypes without the
    neurological features, though the literature records explicit doubt about
    that. Monoallelic variants cause dominant isolated optic atrophy, and that is
    numerically the commonest ACO2 disease: a European screen of genetically
    unsolved inherited optic neuropathies found 50 dominant index cases against 11
    biallelic.

    The dominant disorder is not a subtype of this entry. A has_subtypes record
    under a recessive disease cannot carry a dominant mode of inheritance, and
    inheritance is a split signal rather than a severity gradient. It warrants its
    own Disease entry; see the discussion.
  evidence:
  - reference: PMID:34056600
    reference_title: "Dominant ACO2 mutations are a frequent cause of isolated optic atrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "By screening European cohorts of individuals with genetically unsolved inherited optic neuropathies, we identified 61 cases harbouring variants in ACO2, among whom 50 carried dominant mutations, emphasizing for the first time the important contribution of ACO2 monoallelic pathogenic variants to dominant optic atrophy."
    explanation: >-
      Establishes the dominant optic atrophy entity and its numerical weight
      relative to biallelic disease.
  - reference: PMID:34056600
    reference_title: "Dominant ACO2 mutations are a frequent cause of isolated optic atrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report the identification of 50 index cases carrying heterozygous pathogenic ACO2 variants, together with 11 index cases with biallelic ACO2 mutations."
    explanation: >-
      Quantifies the dominant and recessive case counts recorded in the notes.
  - reference: PMID:32449285
    reference_title: "Recessive ACO2 variants as a cause of isolated ophthalmologic phenotypes."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, some doubt remains as to whether biallelic ACO2 variants can cause isolated ophthalmologic phenotypes."
    explanation: >-
      Records the stated uncertainty about the recessive eye-limited phenotype.
      Marked INDIRECT because it reports the state of the argument rather than
      establishing or excluding the phenotype.
diagnosis:
- name: Plasma metabolomic fingerprint
  description: >-
    Untargeted plasma metabolomics yields a metabolite signature reported as
    diagnostic for mitochondrial aconitase deficiency. This is a useful adjunct
    precisely because the standard mitochondrial workup is unhelpful here: the
    respiratory-chain complexes are normal, so a muscle biopsy assay of the
    complexes will not point at this gene.
  evidence:
  - reference: PMID:28463998
    reference_title: "Plasma metabolomics reveals a diagnostic metabolic fingerprint for mitochondrial aconitase (ACO2) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Taken together we report a diagnostic metabolic fingerprint for mitochondrial aconitase 2 deficiency."
    explanation: >-
      States the diagnostic claim this record describes.
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The activities of the five enzymatic complexes of the mitochondrial respiratory chain and the pyruvate dehydrogenase complex were normal in isolated mitochondria from muscle."
    explanation: >-
      Supports the rationale in this record's description, that a conventional
      respiratory-chain workup will be normal. Marked INDIRECT because it reports
      a negative enzymology result rather than evaluating a diagnostic test.
- name: ACO2 sequencing
  description: >-
    Molecular confirmation. Because the biochemical workup that would normally
    localise a mitochondrial disease is normal in this disorder, sequencing is
    effectively the primary diagnostic route rather than a confirmatory one.
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Homozygosity mapping followed by whole-exome sequencing disclosed a Ser112Arg mutation in ACO2"
    explanation: >-
      The genomic route by which the disease was originally identified.
experimental_models:
- name: Patient-derived skin fibroblasts with compound heterozygous ACO2 variants
  experimental_model_type: PRIMARY_CELL_CULTURE
  publication: PMID:26992325
  description: >-
    Fibroblasts from a patient with compound heterozygous ACO2 missense variants
    of uncertain significance, used to establish pathogenicity functionally and
    to characterise the downstream metabolic consequences.
  modeled_mechanisms:
  - target: Krebs Cycle Flux Block
    relationship: MEASURES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Reports the cellular consequences of the aconitase block in patient tissue:
      deficient respiration, mitochondrial DNA depletion, and altered expression
      of TCA and electron-transport components.
    limitations: >-
      Fibroblasts are not an affected tissue in this disorder, which targets
      cerebellum and retina, so the findings establish that the variants are
      pathogenic and that consequences propagate beyond aconitase itself, not
      that these are the events that kill neurons and photoreceptors. A single
      patient's cells.
    evidence:
    - reference: PMID:26992325
      reference_title: "Functional cellular analyses reveal energy metabolism defect and mitochondrial DNA depletion in a case of mitochondrial aconitase deficiency."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Our findings demonstrate the pathogenicity of two VUS in ACO2, provide novel mechanistic insights to TCA disturbances in ACO2 deficiency, and implicate mitochondrial DNA depletion in the pathogenesis of this recently described disorder."
      explanation: >-
        The authors' own statement of what the model establishes, which is
        pathogenicity plus a downstream mechanism rather than a disease model.
  notes: >-
    No animal model is curated. The review that prompted this section proposed a
    skeletal-muscle-specific Aco2 knockout mouse (PMID:41331265) and an A252T
    knock-in mouse (PMID:38007539). Both were fetched and read: the first is
    titled "Critical role of mitochondrial aconitase in skeletal muscle
    maturation" and studies unloading-induced muscle atrophy; the second is
    titled "ACO2 deficiency increases vulnerability to Parkinson's disease" and
    studies dopaminergic neurodegeneration. Neither mentions infantile
    cerebellar-retinal degeneration at all. They share the gene, not the disease,
    and curating either as a model of this disorder would be the gene-mediated
    Named Entity Confusion the curation rules warn about.

prevalence:
- population: Worldwide, reported cases
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Recorded as a case count rather than a rate because no denominator exists.
    The largest assembled series is 16 patients; the founding report described
    eight individuals from two families. A 2024 report puts the cumulative total
    at roughly 100 patients with aconitase 2 deficiency, which spans the whole
    ACO2 allelic series including the milder OPA9 end rather than this entry
    alone.
  evidence:
  - reference: PMID:30689204
    reference_title: "Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report an international multicenter cohort of 16 patients (of whom 7 are newly diagnosed) with biallelic pathogenic variants in ACO2 gene."
    explanation: >-
      The largest single assembled cohort, which is the basis for the ULTRA_RARE
      band.

treatments:
- name: Triheptanoin anaplerotic therapy
  description: >-
    Triheptanoin, a C7 triglyceride, given to two brothers with ACO2 deficiency.
    It is anaplerotic: its odd-chain metabolites enter the Krebs cycle as
    succinyl-CoA, downstream of the aconitase step, so it refills cycle
    intermediates without requiring the blocked enzyme. Motor abilities improved
    in both patients. This is the only treatment curated here that acts on the
    mechanism rather than on its consequences.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: anaplerotic therapy with triheptanoin
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Krebs Cycle Flux Block
    description: >-
      Bypasses the aconitase step by supplying anaplerotic substrate that enters
      the cycle below the block, which is why it can help without restoring
      aconitase activity.
  notes: >-
    therapeutic_agent is left unbound: triheptanoin has no row in the local CHEBI
    term cache, and a CURIE is never written without reading it from a source in
    the same step. The evidence is two brothers in an open-label in vivo trial
    with a subjective motor endpoint, so this is recorded as a mechanistically
    rational intervention with a promising result, not as established therapy.
  evidence:
  - reference: PMID:38668366
    reference_title: "Anaplerotic Therapy Using Triheptanoin in Two Brothers Suffering from Aconitase 2 Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In an in vivo trial, triheptanoin was used to bypass the defective aconitase 2 and fill up the citric acid cycle. Motor abilities in both patients improved."
    explanation: >-
      States both the mechanistic rationale and the outcome. The n of two and the
      absence of a control are recorded in notes rather than in the grade.
- name: Supportive and rehabilitative care
  description: >-
    Management is otherwise symptomatic: seizure control, feeding and respiratory
    support, and physical therapy for the hypotonia and ataxia. Nothing in this
    tier addresses the enzymatic defect.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  notes: >-
    Recorded without evidence. No publication in this entry's reference cache
    reports a supportive-care outcome in ACO2 deficiency specifically, and the
    tier is named here for completeness rather than cited to a source that does
    not address it. The review that prompted this section proposed NCIT:C133397
    for supportive care, NCIT:C15229 for anticonvulsant therapy and NCIT:C15304
    for physical therapy; read from the NCIT cache, C133397 is Planned End Date
    and C15304 is Plasmapheresis, so none was used. NCIT:C15747 was read from the
    cache at the moment it was written.

discussions:
- discussion_id: aco2_selective_tissue_vulnerability
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Why does loss of a ubiquitous Krebs-cycle enzyme damage the cerebellum, optic
    nerve and retina in particular?
  attaches_to:
  - pathophysiology#Krebs Cycle Flux Block
  - pathophysiology#Progressive Neuronal and Photoreceptor Degeneration
  rationale: >-
    Mitochondrial aconitase is expressed in every tissue with mitochondria, and
    the enzymatic deficit was demonstrated in lymphoblasts - a cell type that is
    not clinically affected. Yet the disease is concentrated in cerebellum, optic
    nerve and retina, with the cortex involved enough to give evolving
    microcephaly and the muscle apparently spared.

    Nothing curated here explains this. The usual candidate accounts - high and
    inflexible energy demand in retinal ganglion cells and their long unmyelinated
    axons, limited metabolic reserve in cerebellar neurons, or a tissue-specific
    consequence of substrate accumulation rather than of ATP shortfall - are
    plausible and untested in this disorder.

    This gap is not decorative. The same selective vulnerability pattern is what
    the dominant ACO2 optic atrophy shows in isolation, so whatever explains the
    tissue selectivity may also explain why a monoallelic dose produces an
    eye-limited disease while a biallelic dose produces a multisystem one.
  evidence:
  - reference: PMID:22405087
    reference_title: "Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Specific aconitase activity in the individuals' lymphoblasts was severely reduced."
    explanation: >-
      Demonstrates the enzymatic deficit in a clinically unaffected cell type,
      which is what makes the tissue selectivity a real question rather than an
      artefact of where the enzyme is expressed.
- discussion_id: aco2_dominant_optic_atrophy_needs_own_entry
  kind: CURATION_TODO
  status: OPEN
  prompt: >-
    Should dominant ACO2-related isolated optic atrophy be a separate dismech
    Disease entry?
  attaches_to:
  - genetic#ACO2
  rationale: >-
    Yes, and this entry deliberately leaves room for it rather than absorbing it.

    Monoallelic ACO2 variants cause isolated dominant optic atrophy, and it is the
    numerically commoner ACO2 disease: 50 dominant index cases against 11
    biallelic in one European screen of unsolved inherited optic neuropathies. It
    cannot be a has_subtypes record under this entry, because a subtype of a
    recessive disease cannot carry dominant inheritance, and dismech treats mode
    of inheritance as a split signal rather than a severity gradient.

    A third presentation sits between them: biallelic variants causing isolated
    ophthalmological phenotypes without neurological features. The literature
    records explicit doubt about whether that entity is real, so it should not be
    curated as established until that doubt resolves.

    Recorded as a CURATION_TODO rather than a knowledge gap because the science is
    settled and the outstanding work is curation.
  evidence:
  - reference: PMID:34056600
    reference_title: "Dominant ACO2 mutations are a frequent cause of isolated optic atrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report the identification of 50 index cases carrying heterozygous pathogenic ACO2 variants, together with 11 index cases with biallelic ACO2 mutations."
    explanation: >-
      Establishes that the dominant entity exists and is numerically substantial,
      which is the case for giving it its own entry.
  - reference: PMID:32449285
    reference_title: "Recessive ACO2 variants as a cause of isolated ophthalmologic phenotypes."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, some doubt remains as to whether biallelic ACO2 variants can cause isolated ophthalmologic phenotypes."
    explanation: >-
      Supports leaving the third, recessive eye-limited presentation uncurated for
      now. Marked INDIRECT because it reports uncertainty rather than a finding.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Infantile Cerebellar-Retinal Degeneration (ACO2, MONDO:0013802) · 2026-09-12T13:35:14Z · View source

De novo curation of infantile cerebellar-retinal degeneration from claim issue #11742. The mechanistically decisive finding is a negative result and it changed the shape of the entry. My own claim issue assumed the chain ran through impaired oxidative phosphorylation. The defining paper measured that and excluded it: the five respiratory-chain complexes and the pyruvate dehydrogenase complex were all normal in muscle mitochondria, while aconitase activity was severely reduced in lymphoblasts. The pathograph therefore routes through a Krebs Cycle Flux Block node rather than an OXPHOS node, and the negative enzymology is recorded as a REFUTE evidence item against the respiratory-chain alternative rather than omitted. This also has a diagnostic consequence, recorded in the diagnosis section: a conventional respiratory-chain assay will be normal in this disease, which is why plasma metabolomics and sequencing carry the diagnostic weight. Lump/split. ACO2 spans three presentations and this entry covers one. Biallelic variants cause this infantile neurological syndrome. Biallelic variants may also cause isolated ophthalmological phenotypes, though the literature records explicit doubt. Monoallelic variants cause dominant isolated optic atrophy, which is numerically the commonest ACO2 disease at 50 dominant index cases against 11 biallelic in one European screen. The dominant disorder is deliberately not modelled as has_subtypes here, because a subtype of a recessive disease cannot carry dominant inheritance and dismech treats mode of inheritance as a split signal. It is recorded in the genetic notes and as a CURATION_TODO discussion recommending its own entry. Deep research: one openscientist report was run and is committed alongside the entry. just preflight-dr returned WARN for a rival gene HP at 30 percent of ACO2 mentions. That is a false positive of a systematic kind: the 40 occurrences are HPO CURIEs of the form HP:0000001, not the haptoglobin gene. The second flagged rival, ACO1, is the yeast aconitase ortholog used for functional complementation in the primary literature and is likewise not a rival disease entity. The report's Term Validation section reported 13 of 14 checked terms as named as a different term, which is itself mostly a false-positive class: the validator reads the adjacent markdown table cell, so a phenotype row whose Type column says Clinical sign is reported as the report calling the CURIE Clinical sign. One curation correction worth recording. The cerebellar atrophy phenotype was first written citing the 16-patient series by its title. That failed snippet validation, correctly, since a title is not a finding. It was replaced with two serial-MRI sentences from the full text of the founding paper. Validation: just validate passed with 30/30 snippets verified; just validate-terms passed; check-duplicate-keys, check-entity-refs, check-causal-targets and check-qualifier-terms all clean.

OpenScientist ▸
Infantile Cerebellar-Retinal Degeneration (ICRD): A Comprehensive Disease Characterization Report
openscientist-autonomous 23 citations 2026-09-12T13:24:17.879119

Infantile Cerebellar-Retinal Degeneration (ICRD): A Comprehensive Disease Characterization Report

Disease: Infantile Cerebellar-Retinal Degeneration MONDO ID: MONDO:0013802 · OMIM: #614559 · Orphanet: ORPHA:314629 Category: Mendelian (autosomal recessive neurometabolic disorder) Causal gene: ACO2 (mitochondrial aconitase; HGNC:118; UniProt Q99798)

Summary

Infantile Cerebellar-Retinal Degeneration (ICRD) is an ultra-rare, autosomal recessive, infantile-onset neurometabolic and neurodegenerative disorder caused by biallelic loss-of-function variants in ACO2, the nuclear-encoded gene for mitochondrial aconitase — the second enzyme of the tricarboxylic acid (TCA)/Krebs cycle, which interconverts citrate and isocitrate via a catalytic [4Fe-4S] iron–sulfur cluster. Disease was first defined in 2012 by homozygosity mapping and whole-exome sequencing in two families sharing a homozygous p.Ser112Arg (c.336C>G) founder mutation, with severely reduced aconitase activity in patient lymphoblasts and failure of the mutant human enzyme to rescue a yeast aconitase-null strain (PMID: 22405087).

Clinically, ICRD presents in early infancy (typically 2–6 months) with severe truncal hypotonia, truncal ataxia, evolving microcephaly, variable seizures, and progressive ophthalmologic disease — esotropia and optic atrophy followed by retinal dystrophy. Brain MRI is usually normal in the first months but develops progressive global atrophy that is predominantly cerebellar. Most patients remain nonambulatory and nonverbal, though the phenotype is a genuine spectrum: at the severe end, infantile death; at the mild end, isolated optic atrophy 9 (OPA9) with preserved cognition and normal lifespan. This allelic-series relationship (severe ICRD ↔ mild OPA9) is a defining feature of ACO2 disease.

Mechanistically, aconitase deficiency produces a coherent causal chain: (1) mutation damages the catalytic [4Fe-4S] cluster or substrate-binding residues → (2) loss of citrate→isocitrate conversion → (3) TCA-cycle/bioenergetic failure with secondary mitochondrial DNA depletion and deficient respiration → (4) toxic citrate accumulation that activates the integrated stress response (ISR) → (5) caspase-3–mediated apoptosis and reduced histone-acetylation–driven autophagy suppression → (6) preferential death of high-energy-demand neurons (cerebellar, retinal, optic) → (7) the clinical phenotype. Management is currently supportive; anaplerotic triheptanoin (an odd-chain C7 triglyceride that refills TCA intermediates downstream of the aconitase block) has been trialed in two brothers as a rational but still-unproven disease-directed therapy.

Section 1 — Disease Information

Overview. ICRD is a Mendelian mitochondrial-adjacent (nuclear gene, mitochondrial enzyme) neurodegenerative disease of infancy defined by the triad of progressive cerebellar degeneration, retinal/optic degeneration, and global developmental delay/regression. It is a distinct clinical entity within the broader group of ACO2-related disorders.

Key identifiers.

Resource Identifier
MONDO MONDO:0013802
OMIM #614559 (Infantile cerebellar-retinal degeneration)
Orphanet ORPHA:314629
Gene (HGNC) ACO2, HGNC:118
Gene OMIM 100850
UniProt (protein) Q99798 (Aconitate hydratase, mitochondrial)
Ensembl ENSG00000100412

Synonyms / alternative names. ICRD; ACO2-related infantile cerebellar-retinal degeneration; mitochondrial aconitase deficiency; aconitase 2 (ACO2) deficiency. The allelic milder disorder is Optic Atrophy 9 (OPA9).

Source of information. The knowledge base entry is derived from aggregated disease-level resources (OMIM, Orphanet) and from individual-patient primary literature — small case series and cohorts (the largest being 16 patients, PMID: 30689204) and single case reports. No EHR-scale population data exist given disease rarity.

Section 2 — Etiology

Primary cause (genetic). ICRD is caused exclusively by biallelic (homozygous or compound heterozygous) pathogenic variants in ACO2. There is no environmental or infectious etiology. The founding study established causality through homozygosity mapping plus WES, biochemical demonstration of severely reduced aconitase activity, and a yeast complementation assay in which mutant human ACO2 failed to rescue an ACO1-deletion strain (PMID: 22405087). A 16-patient multicenter cohort confirmed biallelic pathogenic ACO2 variants as the recurrent cause (PMID: 30689204).

Genetic risk factors. The causal variants themselves are the risk factor. A recurrent founder allele c.336C>G (p.Ser112Arg) appeared in 10 of 16 patients in the largest cohort (PMID: 30689204). ACO2 is highly constrained against variation in gnomAD (pLI 0.97; missense-Z 4.58; LoF-Z 4.94), consistent with an essential gene whose complete loss is not tolerated (Finding F004).

Environmental / protective factors, gene–environment interactions. None established. As a fully penetrant Mendelian recessive disorder, there are no recognized environmental risk factors, protective alleles, or GxE interactions. Consanguinity elevates recurrence risk of the recessive genotype but is not a disease cause per se.

Section 3 — Phenotypes

Phenotypes are drawn chiefly from the 16-patient cohort (PMID: 30689204) and the founding cohort (PMID: 22405087). Onset is neonatal-to-early-infantile; course is progressive.

Phenotype Type HPO term Onset / severity / frequency
Truncal hypotonia Clinical sign HP:0008936 Early infancy; severe; most patients
Truncal ataxia Clinical sign HP:0002078 Infancy; severe; most patients
Optic atrophy Physical/ophthalmologic HP:0000648 Infancy→childhood; dominant feature
Esotropia Clinical sign HP:0000565 Infancy; most dominant ocular sign
Retinal dystrophy/degeneration Physical HP:0000556 Later than optic atrophy; progressive
Seizures Clinical sign HP:0001250 Variable; subset of patients
Microcephaly (evolving/acquired) Physical HP:0000252 / HP:0005484 Postnatal, progressive
Global developmental delay Behavioral/cognitive HP:0001263 Infancy; severe; most patients
Intellectual disability Cognitive HP:0001249 Severe–profound (variable)
Cerebellar atrophy Imaging HP:0001272 Develops after normal early MRI
Cerebral (cortical) atrophy Imaging HP:0002059 Progressive
Absent speech/language Behavioral HP:0001344 Most remain nonverbal
Peripheral neuropathy Clinical sign HP:0009830 Reported in longer-surviving cases (PMID 28545339)
Pigmentary retinopathy Physical HP:0000580 Reported in moderate/older cases

Characteristics summary (F008): Most patients present in early infancy with "severe truncal hypotonia, truncal ataxia, variable seizures, evolving microcephaly, and ophthalmological abnormalities of which the most dominant are esotropia and optic atrophy with later development of retinal dystrophy" (PMID: 30689204). "Brain magnetic resonance imaging (MRI) is typically normal within the first months but global atrophy gradually develops affecting predominantly the cerebellum" (same source). The founding study documented onset at 2–6 months with survival up to 18 years (PMID: 22405087).

Severity spectrum. Severe (infantile death) → moderate (increased survival with partly preserved cognition; a patient able to "speak full sentences and follow commands," PMID: 28545339) → mild isolated optic atrophy (OPA9).

Quality-of-life impact. Profound in classic ICRD: most patients are nonambulatory, nonverbal, visually impaired, and fully dependent for daily activities, with high caregiver burden. No formal EQ-5D/SF-36 instruments have been applied given rarity.

Section 4 — Genetic / Molecular Information

Causal gene. ACO2 (aconitase 2, mitochondrial), HGNC:118, chr22q13.2 (GRCh38 chr22:41,447,830–41,529,273), Ensembl ENSG00000100412, protein UniProt Q99798 (780 aa).

Representative pathogenic variants.

Variant (protein) cDNA Type Significance Note / PMID
p.Ser112Arg c.336C>G Missense (founder) Pathogenic First ICRD variant; 10/16 cohort; 22405087, 30689204
p.Cys448Ser — Missense Pathogenic Removes [4Fe-4S] cluster ligand; 32713659
p.Met393Ile — Missense Likely pathogenic Adjacent to Cys385 cluster ligand; 32713659

Variant classification & type. Variants are predominantly missense, classified pathogenic/likely-pathogenic by ACMG/AMP criteria supported by functional enzyme assays. Nonsense/frameshift alleles also occur. Given strong LoF constraint (gnomAD LoF-Z 4.94, pLI 0.97), complete biallelic null genotypes may be embryonic-lethal, which is consistent with the missense-heavy spectrum observed in survivors.

Allele frequency. Pathogenic alleles are ultra-rare in gnomAD; overall ACO2 is strongly depleted of both missense and LoF variation (Finding F004).

Origin & functional consequence. All disease alleles are germline; there is no somatic/cancer role. The molecular consequence is loss of function — reduced aconitase catalytic activity (patient fibroblasts <20% of control; PMID: 26992325), reduced cellular respiration, and secondary mitochondrial DNA depletion, all rescued by reintroducing wild-type ACO2 (same study).

Structural basis (F005). UniProt Q99798 annotates an N-terminal mitochondrial transit peptide (aa 1–27), substrate-binding residues (99, 192–194, 474, 479, 607, 670–671), and three [4Fe-4S] cluster-coordinating cysteines at 385, 448, 451. p.Cys448Ser eliminates one cluster ligand; p.Met393Ile sits immediately adjacent to Cys385 — providing a direct structural explanation for enzyme failure.

Modifier genes / epigenetics / chromosomal abnormalities. No specific modifier genes are established; residual aconitase activity (allele-dependent) is the principal severity determinant. Notably, LONP1 protease regulates ACO2 turnover/stability (PMID: 42302976), a plausible modifier axis. Downstream epigenetic dysregulation (histone acetylation) is a consequence, not a cause (see Section 6). No recurrent large chromosomal abnormalities are associated with ICRD.

Section 5 — Environmental Information

Not applicable. ICRD is a monogenic recessive disorder with no environmental, lifestyle, toxic, or infectious contributors. General mitochondrial stressors (oxidative stress, aminoglycoside-class mitochondrial toxins) are theoretical aggravators of any bioenergetic disorder but have no disease-specific evidence in ICRD. Aconitase is intrinsically redox-sensitive (its [4Fe-4S] cluster is inactivated by superoxide, H₂O₂, NO, ONOO⁻; PMID: 9171919, PMID: 24266943), so oxidative burden could in principle worsen residual enzyme activity, but this is inferred, not demonstrated in patients.

Section 6 — Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

  1. Biallelic ACO2 mutation damages a substrate-binding residue or a [4Fe-4S] cluster-coordinating cysteine (e.g., Cys448Ser) → leads to loss/instability of the catalytic iron–sulfur cluster. (Demonstrated: enzyme activity <20% of control; F003, F005.)
  2. Cluster/enzyme failure → results in inability to convert citrate → cis-aconitate → isocitrate in the TCA cycle. (Demonstrated: altered plasma cis-aconitate, isocitrate, α-ketoglutarate; F003.)
  3. TCA-cycle block → leads to impaired NADH/FADH₂ supply and bioenergetic (ATP) failure, with deficient cellular respiration and secondary mitochondrial DNA depletion. (Demonstrated in fibroblasts; F003, PMID: 26992325.)
  4. Branch A — Citrate accumulation (failure of citrate clearance) → activates the integrated stress response (ISR) and impairs cell fitness; reversible by blocking citrate production or promoting citrate efflux. (Demonstrated in cells and kidney in vivo; F007, PMID: 41763199.)
  5. Branch B — Energy/metabolic stress → reduced histone acetylation (H3K9, H4K5) → downregulation of autophagy genes LC3/Atg5 → impaired autophagic clearance. (Demonstrated in ACO2-deficient PD model; F007, PMID: 38007539.)
  6. ISR + energy failure + defective autophagy → caspase-3–mediated apoptosis of vulnerable cells. (Demonstrated: Active Caspase-3 up, muscle Aco2-KO; F007, PMID: 41331265.)
  7. Preferential loss of high-energy-demand, post-mitotic neurons — cerebellar (Purkinje/granule) neurons, retinal photoreceptors/ganglion cells, optic nerve axons → results in progressive cerebellar atrophy, retinal degeneration, optic atrophy, hypotonia, ataxia, seizures, and developmental regression (the ICRD phenotype). (Clinical–imaging correlation; F008.)
ACO2 mutation ([4Fe-4S] ligand loss)
│
▼
 Aconitase activity ↓↓ (<20%)
│
▼
 Citrate ⇢ isocitrate block  ──► TCA metabolite shift (cis-aconitate↑, isocitrate/α-KG altered)
│                                   │
▼                                   ▼
 Respiration ↓, ATP ↓                 Citrate accumulation
 mtDNA depletion                            │
│                                   ▼
│                          Integrated Stress Response (ISR)
│                                   │
├──────────────┬────────────────────┤
▼              ▼                     ▼
 Histone acetyl↓   Autophagy↓           Caspase-3 apoptosis
 (H3K9/H4K5)       (LC3/Atg5↓)
└──────────────┴────────────────────┘
        │
        ▼
   Death of high-energy neurons (cerebellum, retina, optic nerve)
        │
        ▼
   Progressive cerebellar/retinal degeneration → ICRD phenotype

Molecular pathways. TCA/Krebs cycle (KEGG hsa00020), oxidative phosphorylation, iron–sulfur cluster biogenesis, integrated stress response. Cellular processes (GO): TCA cycle (GO:0006099), aconitate hydratase activity (GO:0003994), 4Fe-4S cluster binding (GO:0051539), generation of precursor metabolites and energy (GO:0006091), autophagy (GO:0006914), apoptotic process (GO:0006915), response to oxidative stress (GO:0006979). Protein dysfunction: loss-of-function via cluster destabilization/misassembly. Metabolic changes: TCA intermediate flux disruption (diagnostic plasma fingerprint — cis-aconitate, isocitrate, α-KG, phosphoenolpyruvate, hydroxybutyrate; PMID: 28463998); elevated glutamate reported (PMID: 32713659). Tissue damage: oxidative-stress-sensitive enzyme, bioenergetic starvation, apoptosis. Immune involvement: none primary (mtDNA release can secondarily engage cGAS-STING inflammation via LONP1 axis — inferred, PMID: 42302976).

Subcellular localization (GO Cellular Component): mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759). Cell types (CL): cerebellar Purkinje cell (CL:0000121), cerebellar granule cell (CL:0001031), retinal photoreceptor (CL:0000210), retinal ganglion cell (CL:0000740). Anatomy (UBERON): cerebellum (UBERON:0002037), retina (UBERON:0000966), optic nerve (UBERON:0000941).

Comparison to related disease. In Friedreich ataxia, frataxin loss secondarily impairs Fe-S enzymes including aconitase, producing mitochondrial iron accumulation and Fe-S enzyme deficiency (PMID: 9326946) — a mechanistic cousin (Fe-S/aconitase failure) reached by a different primary lesion.

Section 7 — Anatomical Structures Affected

  • Primary organs/systems: central nervous system (nervous system) — cerebellum (predominant), cerebral cortex, optic nerve, and retina/eye.
  • Secondary involvement: peripheral nerves (neuropathy in longer survivors), skeletal muscle (hypotonia; muscle maturation depends on ACO2 in models).
  • Tissue level: nervous tissue (neurons and their axons), retinal neuroepithelium.
  • Cell populations (CL): cerebellar Purkinje cells (CL:0000121), granule cells (CL:0001031), retinal photoreceptors (CL:0000210), retinal ganglion cells (CL:0000740), optic nerve axons.
  • Subcellular (GO CC): mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759).
  • Localization / lateralization: bilateral, symmetric CNS atrophy; bilateral optic atrophy and retinal degeneration. UBERON: cerebellum UBERON:0002037, retina UBERON:0000966, optic nerve UBERON:0000941, cerebral cortex UBERON:0000956.

Section 8 — Temporal Development

  • Onset: congenital-to-early-infantile; typical symptomatic onset 2–6 months of age (PMID: 22405087); pattern insidious then progressive.
  • Progression: progressive neurodegeneration. MRI is characteristically normal in the first months, then develops progressive global atrophy, predominantly cerebellar (PMID: 30689204). Rate is variable and genotype-dependent.
  • Course: chronic, lifelong, non-remitting. Severe end → death in infancy; moderate → survival into teens (up to 18 years documented) with preserved-but-limited function; mild (OPA9) → normal lifespan.
  • Critical period: the early-infantile window before irreversible cerebellar/retinal cell loss is the theoretical target for any future disease-modifying (e.g., anaplerotic or gene) therapy.

Section 9 — Inheritance and Population

  • Inheritance: autosomal recessive (biallelic ACO2). The allelic dominant disorder (isolated optic atrophy) exists separately (PMID: 34056600).
  • Penetrance: effectively complete for biallelic pathogenic genotypes.
  • Expressivity: highly variable — an allelic series from OPA9 (mild) to lethal infantile ICRD, largely reflecting residual enzyme activity.
  • Founder effect: yes — c.336C>G (p.Ser112Arg) recurrent (10/16 cohort; PMID: 30689204).
  • Consanguinity: contributes (homozygous founder cases identified by homozygosity mapping).
  • Anticipation / germline mosaicism: not reported / not applicable.
  • Epidemiology: ultra-rare; fewer than ~40 patients/families reported worldwide (initial reports noted only ~6 families/5 unique mutations; PMID: 28545339). No reliable prevalence/incidence estimates; Orphanet lists it as <1/1,000,000.
  • Sex ratio / demographics: no strong sex bias (autosomal recessive); reported across multiple ethnicities (Middle Eastern founder families, Chinese, European cases).

Section 10 — Diagnostics

Genetic testing (definitive). Diagnosis rests on identifying biallelic pathogenic ACO2 variants by whole-exome (WES) or whole-genome sequencing (WGS), or a mitochondrial/cerebellar-ataxia/retinal-dystrophy gene panel that includes ACO2; targeted testing for the founder c.336C>G in relevant populations. Sanger confirmation and parental segregation establish compound heterozygosity (PMID: 32713659, PMID: 22405087).

Biochemical / functional tests. Reduced aconitase enzyme activity in lymphoblasts/fibroblasts (<20% control) supports pathogenicity; mtDNA copy number (depletion) and cellular respiration assays are confirmatory research tools (PMID: 26992325).

Metabolomic biomarker. A plasma metabolomic fingerprint — altered cis-aconitate, isocitrate, α-ketoglutarate, phosphoenolpyruvate, and hydroxybutyrate — serves as a diagnostic signature (PMID: 28463998).

Imaging. Brain MRI — serial imaging shows evolving global atrophy predominantly cerebellar; optic nerve atrophy (PMID: 30689204). Ophthalmologic workup — fundoscopy (optic atrophy, pigmentary retinopathy), visual electrophysiology (ERG/VEP) demonstrating optic atrophy and retinal dysfunction (PMID: 40210596).

Differential diagnosis. Other infantile cerebellar-atrophy-plus-retinopathy syndromes: neuronal ceroid lipofuscinoses (CLN6, MFSD8/CLN7; PMID: 39108195), spinocerebellar ataxia type 7 (ATXN7 repeat; PMID: 37283503), Norrie disease (PMID: 39965923), Friedreich ataxia, other mitochondrial/Fe-S disorders, and PKAN. ACO2 sequencing plus the TCA metabolite fingerprint distinguishes ICRD.

Screening. Carrier/cascade testing in founder-carrying families; prenatal/preimplantation testing where the familial variants are known. Not part of standard newborn-screening panels.

Section 11 — Outcome / Prognosis

  • Survival: highly variable by genotype. Severe cases → death in infancy/early childhood; classic cases survive into childhood/teens (up to 18 years reported; PMID: 22405087, PMID: 28545339); OPA9 → normal lifespan.
  • Morbidity / function: severe in classic ICRD — most patients are nonambulatory, nonverbal, cortically/optically visually impaired, with intractable epilepsy in a subset and profound intellectual disability; fully care-dependent.
  • Complications: seizures, aspiration/feeding difficulty from hypotonia, contractures, vision loss, and secondary infections typical of severe neurodisability.
  • Recovery potential: none — the disease is progressive and neurodegenerative; supportive care is stabilizing at best.
  • Prognostic factors: residual aconitase activity/genotype is the dominant determinant (missense with partial function → longer survival and partial cognition, e.g., PMID: 28545339); degree/rate of cerebellar atrophy on serial MRI; seizure burden.

Section 12 — Treatment

No disease-specific approved therapy exists. Management is supportive and multidisciplinary: antiepileptic drugs for seizures, physical/occupational/speech therapy for hypotonia and developmental support, nutritional support (gastrostomy where needed), low-vision services and ophthalmologic management, and orthopedic care for contractures. (NCIT: supportive care NCIT:C133397; anticonvulsant therapy NCIT:C15229; physical therapy NCIT:C15304.)

Experimental disease-directed therapy — anaplerosis. Triheptanoin (an odd-chain C7 triglyceride) was administered to two brothers with aconitase 2 deficiency — the first reported disease-directed metabolic intervention for ACO2 deficiency (PMID: 38668366). Rationale: triheptanoin is metabolized to propionyl-CoA → succinyl-CoA, refilling TCA-cycle intermediates downstream of the aconitase block (anaplerosis), theoretically bypassing the citrate→isocitrate lesion. Efficacy remains unproven pending controlled data.

Mechanistically-motivated (preclinical/speculative) targets: promoting mitochondrial citrate efflux or limiting citrate production (reverses ISR/fitness defects in cell/kidney models; PMID: 41763199); the ACO2-metabolite derivative 4-octyl itaconate rescued mitochondrial dysfunction/apoptosis from ACO2 deficiency in a lung model (PMID: 41637882); antioxidant strategies given cluster redox sensitivity (theoretical). Gene therapy/gene replacement is a rational future direction (WT-ACO2 reintroduction fully rescues the cellular phenotype in vitro; PMID: 26992325) but not yet clinical.

Pharmacogenomics / immunotherapy / surgery: not applicable as disease-modifying modalities.

Section 13 — Prevention

  • Primary prevention: not possible for a germline recessive disorder beyond reproductive planning.
  • Genetic counseling & reproductive options: the mainstay — carrier testing for at-risk couples (especially consanguineous families and founder-allele populations), prenatal diagnosis and preimplantation genetic testing (PGT) when familial variants are known, and cascade testing of relatives.
  • Secondary/tertiary prevention: early recognition (metabolite fingerprint + genetics) enables early supportive intervention, seizure control, and complication prevention (aspiration, contractures) — no intervention halts neurodegeneration.
  • Immunization / public-health / environmental measures: not applicable.

Section 14 — Other Species / Natural Disease

  • Orthologs: ACO2 is deeply conserved. Mouse Aco2 (NCBI Gene 11429); Drosophila ortholog mAcon1; yeast ACO1 (functional complementation used to prove human causality, PMID: 22405087). Bacterial aconitases (E. coli AcnA/AcnB) share the [4Fe-4S] cluster architecture with the mammalian mitochondrial enzyme (PMID: 10585860).
  • Natural disease in other species: no well-characterized spontaneous ACO2-deficiency disorder in companion animals/wildlife is reported (OMIA); disease knowledge is from engineered models.
  • Comparative biology: aconitase's dual role (TCA catalysis + Fe-S/iron sensing) and its redox sensitivity are conserved from bacteria to humans (PMID: 24266943, PMID: 17205209), making cross-species mechanistic inference robust.
  • Zoonosis: not applicable.

Section 15 — Model Organisms

Model Type Key findings PMID
Constitutive/skeletal-muscle Aco2 knockout mouse Mammalian, KO Mice die shortly after birth; muscle fiber atrophy, disrupted sarcomeres, increased Active Caspase-3 (apoptosis); aconitase essential for muscle maturation 41331265
ACO2 A252T knock-in mouse Mammalian, KI Aggravated dopaminergic neurodegeneration; downregulated autophagy (LC3, Atg5) via reduced H3K9/H4K5 histone acetylation 38007539
Drosophila (mAcon1) Invertebrate Pan-neuronal knockdown/overexpression reduces longevity, locomotion, activity; disrupts sleep/circadian rhythm; eye mis-expression → impaired visual synaptic transmission and neurodegeneration — mirrors human ICRD 40210596
Patient fibroblasts In vitro (cellular) Aconitase activity <20%, deficient respiration, mtDNA depletion; fully rescued by WT-ACO2 reintroduction 26992325
Yeast (ACO1Δ) complementation Cellular Mutant human ACO2 fails to rescue aconitase-null yeast — proves loss of function 22405087

Phenotype recapitulation: the Drosophila model recapitulates neuronal dysfunction, visual/retinal degeneration, and locomotor decline; the knock-in mouse recapitulates the metabolism→epigenetics→autophagy→neurodegeneration axis. Limitations: constitutive KO is lethal (limiting adult CNS study without conditional alleles), and no model perfectly reproduces the full human cerebellar-retinal-cognitive triad.

Key Findings (with statistical evidence)

F001 — ICRD is caused by biallelic ACO2 variants. Homozygosity mapping + WES in 8 individuals from 2 families identified homozygous p.Ser112Arg (c.336C>G); patient lymphoblast aconitase activity was severely reduced, and mutant human ACO2 failed to complement a yeast ACO1 deletion. "Homozygosity mapping followed by whole-exome sequencing disclosed a Ser112Arg mutation in ACO2, encoding mitochondrial aconitase… Specific aconitase activity in the individuals' lymphoblasts was severely reduced" (PMID: 22405087). A 16-patient cohort confirmed biallelic pathogenic variants (PMID: 30689204).

F002 — Phenotypic spectrum from OPA9 to severe ICRD. "Biallelic variants in ACO2 are purported to cause two distinct disorders: infantile cerebellar-retinal degeneration (ICRD)… and optic atrophy 9 (OPA9), characterized by isolated ophthalmologic phenotypes" (PMID: 32449285). Dominant ACO2 variants also cause isolated optic atrophy (PMID: 34056600).

F003 — Metabolomic fingerprint and cellular energy defects. "…metabolites with affected plasma concentrations including the tricarboxylic acid cycle metabolites cis-aconitate, isocitrate and alpha-ketoglutarate, as well as phosphoenolpyruvate and hydroxybutyrate" (PMID: 28463998). "ACO2 enzyme activity was <20% of that observed in control cells… deficiency in cellular respiration and, for the first time,… mitochondrial DNA depletion" — rescued by gene reintroduction (PMID: 26992325).

F004 — Strong gnomAD constraint. ACO2 (ENSG00000100412): pLI 0.97, LOEUF 0.495 (o/e LoF 0.367), missense-Z 4.58, LoF-Z 4.94 — an essential, constraint-heavy gene, consistent with recessive ICRD and dominant optic-atrophy mechanisms.

F005 — Variants strike catalytic Fe-S residues. UniProt Q99798 annotates [4Fe-4S] ligands Cys385/448/451; p.Cys448Ser removes a ligand and p.Met393Ile lies adjacent to Cys385 (PMID: 32713659).

F006 — Triheptanoin anaplerotic therapy trialed. First disease-directed metabolic intervention: "Anaplerotic Therapy Using Triheptanoin in Two Brothers Suffering from Aconitase 2 Deficiency" (PMID: 38668366).

F007 — Citrate accumulation → ISR → apoptosis; KO lethal. "Disrupting citrate catabolism activates the integrated stress response and impairs cell fitness… reversed by preventing citrate production or promoting mitochondrial citrate efflux. In vivo, ACO2 deficiency induces citrate accumulation and triggers tubular degeneration in the kidney" (PMID: 41763199). Muscle Aco2-KO mice "died shortly after birth" with caspase-3 apoptosis (PMID: 41331265). "…autophagy-related genes LC3 and Atg5 was significantly downregulated via inhibited histone acetylation at the H3K9 and H4K5 sites" (PMID: 38007539).

F008 — Characteristic clinical/MRI course. "Most patients present in early infancy with severe truncal hypotonia, truncal ataxia, variable seizures, evolving microcephaly, and ophthalmological abnormalities of which the most dominant are esotropia and optic atrophy with later development of retinal dystrophy" and "Brain MRI is typically normal within the first months but global atrophy gradually develops affecting predominantly the cerebellum" (PMID: 30689204).

Mechanistic Model / Interpretation

ICRD is best understood as a primary bioenergetic + citrate-toxicity disorder of neurons. The single enzymatic lesion (aconitase failure) produces two converging insults: (i) an energy-supply deficit (TCA flux ↓, respiration ↓, mtDNA depletion), and (ii) a toxic-substrate accumulation (citrate build-up) that actively triggers the integrated stress response, apoptosis, and epigenetically-mediated autophagy suppression. These converge on the death of post-mitotic, high-energy-demand cells — cerebellar neurons, retinal photoreceptors and ganglion cells, and optic nerve axons — explaining the disease's signature cerebellar-retinal predilection. The allelic series (OPA9 ↔ ICRD) is naturally explained by a residual-activity model: variants with partial function spare the CNS and manifest only in the exquisitely oxidative-metabolism-dependent optic system, while near-null biallelic genotypes produce lethal multisystem disease. The finding that citrate efflux, blocking citrate production, or 4-octyl itaconate can reverse cellular phenotypes, and that WT-ACO2 fully rescues fibroblasts, identifies actionable, druggable nodes downstream of the mutation.

Evidence Base

PMID Contribution Source type
22405087 Establishes ACO2 causality; founder variant; yeast complementation Human + in vitro
30689204 Largest cohort (n=16); clinical/MRI delineation; founder frequency Human clinical
32449285 ICRD↔OPA9 spectrum Human clinical
34056600 Dominant ACO2 optic atrophy Human clinical
26992325 Enzyme <20%, respiration defect, mtDNA depletion, gene rescue In vitro
28463998 Plasma metabolomic diagnostic fingerprint Human biomarker
32713659 Cys448Ser / Met393Ile — Fe-S cluster structural basis Human + structural
28545339 Moderate phenotype, preserved cognition, longer survival Human clinical
41763199 Citrate clearance → ISR → cell fitness (2026) In vitro + mouse
41331265 Aco2 KO lethal; caspase-3 apoptosis (2025) Mouse
38007539 Metabolism→histone-acetylation→autophagy axis Mouse + fly
40210596 Drosophila ICRD model recapitulating neuro/visual phenotypes Invertebrate
38668366 Triheptanoin anaplerotic therapy Human (n=2)
9326946 Aconitase/Fe-S deficiency in Friedreich ataxia (comparator) Human

Limitations and Knowledge Gaps

  • Ultra-rarity: Total reported patients number in the low dozens; no prevalence/incidence, no natural-history registry, no formal QoL data.
  • Genotype–phenotype correlations are inferred from small cohorts; the residual-activity model is plausible but not quantitatively validated across the allelic series.
  • No CNS-specific animal model fully recapitulates the human cerebellar-retinal-cognitive triad; constitutive KO lethality limits adult neuro-study without conditional alleles.
  • Therapeutics unproven: triheptanoin evidence is anecdotal (n=2, no controls); downstream targets (citrate efflux, 4-OI, antioxidants) are preclinical only; no gene therapy in trials.
  • Mechanistic branches (ISR, epigenetic-autophagy, apoptosis) are largely demonstrated in non-neuronal or non-human systems and inferred for the patient CNS.
  • Some causal steps (oxidative-stress aggravation, immune/cGAS-STING involvement) remain inferred, not demonstrated, in ICRD patients.

Proposed Follow-up Experiments / Actions

  1. Patient-derived iPSC cerebellar and retinal organoids carrying defined ACO2 alleles to directly test the citrate-toxicity/ISR/apoptosis chain in the affected human cell types and to correlate residual enzyme activity with degeneration rate.
  2. Conditional (neuron- and photoreceptor-specific) Aco2 knockout / knock-in mice to bypass embryonic lethality and model CNS/retinal disease longitudinally.
  3. Controlled anaplerosis trial: formal evaluation of triheptanoin (and comparison with citrate-efflux promotion or 4-octyl itaconate) using the plasma TCA-metabolite fingerprint as a pharmacodynamic biomarker.
  4. AAV-mediated ACO2 gene replacement proof-of-concept in models, leveraging the demonstrated full cellular rescue by WT-ACO2.
  5. Prospective natural-history study and registry with standardized serial MRI (cerebellar volumetrics), ERG/VEP, and developmental metrics to define progression and trial endpoints.
  6. Structure-guided variant classification: map all reported variants onto the aconitase [4Fe-4S] and substrate-binding architecture (Q99798) and correlate predicted structural impact with clinical severity to formalize the residual-activity model.

Report compiled from 8 confirmed findings and 32 reviewed papers across 5 investigation iterations. Evidence types are distinguished as human clinical, model organism, in vitro/cellular, and computational/structural throughout.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 23
Resolved 23
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 2
Quoted claims found in source 2
Quoted claims not found in source 0
References weighed for topical relevance 23
On topic 16
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 38
Resolved 36
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 2
Terms whose name was checked 14
Terms named correctly 0
Terms named as a different term 13
Terms whose name is worth a second look 1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0013802 (2 mentions) - the report calls it "MONDO"; MONDO calls it infantile cerebellar-retinal degeneration
  • HP:0008936 (1 mention) - the report calls it "Clinical sign"; HP calls it Axial hypotonia
  • HP:0002078 (1 mention) - the report calls it "Clinical sign"; HP calls it Truncal ataxia
  • HP:0000648 (1 mention) - the report calls it "Physical/ophthalmologic"; HP calls it Optic atrophy
  • HP:0000565 (1 mention) - the report calls it "Clinical sign"; HP calls it Esotropia
  • HP:0000556 (1 mention) - the report calls it "Physical"; HP calls it Retinal dystrophy
  • HP:0001250 (1 mention) - the report calls it "Clinical sign"; HP calls it Seizure
  • HP:0001249 (1 mention) - the report calls it "Cognitive"; HP calls it Intellectual disability
  • HP:0001272 (1 mention) - the report calls it "Imaging"; HP calls it Cerebellar atrophy
  • HP:0002059 (1 mention) - the report calls it "Imaging"; HP calls it Cerebral atrophy
  • HP:0001344 (1 mention) - the report calls it "Behavioral"; HP calls it Absent speech
  • HP:0009830 (1 mention) - the report calls it "Clinical sign"; HP calls it Peripheral neuropathy
  • HP:0000580 (1 mention) - the report calls it "Physical"; HP calls it Pigmentary retinopathy

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0001263 (1 mention) - the report calls it "Behavioral/cognitive"; HP calls it Global developmental delay, and lists "Cognitive delay" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.